WELL — Welltower Inc.

Sentiment as of 2026-09-13 is bullish but no longer euphoric. The July 27, 2026 Q2 print beat on revenue ($3.54B vs. ~$3.40B consensus) and management raised FY26 normalized FFO guidance to $6.36-$6.44 from $6.21-$6.35, with blended same-store NOI growth guided to 13.75%-16.00% and Seniors Housing Operating NOI up 20.5% YoY on +100bps sequential spot occupancy and RevPOR of $6,059 (+5.2%). The June 2026 15% dividend increase to $0.85/quarter confirmed cash-flow conversion. Sell-side is aligned: 1 strong buy, 24 buys, 10 holds, zero sells, with a $256.31 average target. What keeps this from being a melt-up is valuation - the stock sits 7.7% off its $255.20 52-week high with a flat -0.08% last session, a 122x trailing P/E, and a deterministic valuation flag of 'Rich vs. its own history' (P/S of 13.46x vs. a 5-year average of 8.28x).

Revenue has compounded for 11 of the last 12 quarters: $1.63B in Q3 2023 to $3.54B in Q2 2026, and the growth rate has inflected higher, not faded. YoY revenue growth ran +23.6% in Q3 2024, +29.2% in Q4 2024, +30.5% in Q1 2025, then jumped to +40.3% / +30.7% / +41.2% / +38.4% / +40.9% across Q2 2025 through Q2 2026 - roughly 40% growth sustained for three straight quarters. Gross margin is stable at 39-40% (Q2 2026: 39.3%), so this is top-line and occupancy-driven, not margin-driven. Operating cash flow is accelerating even faster: Q2 2026 OCF of $1.20B was +55.9% YoY versus Q2 2025's $770M, and FCF reached $881M versus $761M. GAAP net income is the one noisy line - it swings from $96M in Q4 2025 (dragged by a -$943.7M operating loss, i.e., a large impairment) to $728.7M in Q1 2026 (flattered by disposition gains) - which is exactly why REIT investors should judge this on FFO/SSNOI rather than EPS. Verdict: structural acceleration, not a blip.

Expensive on every lens except the one that is distorted. As of 2026-09-13 the trailing P/E is 122.0x against a 5-year average of 133.6x, which superficially looks 'cheap vs. own history' but is meaningless for a REIT whose GAAP earnings are crushed by depreciation and a $943.7M Q4 2025 impairment. The cleaner signals are uniformly rich: P/S of 13.46x versus a 5-year average of 8.28x, P/B of 3.58x, EV/EBITDA around 63x on the ratio screener, PEG of 15.6, and a 1.33% trailing dividend yield (1.44% on the new $3.40 annualized rate). On the metric that matters, price/FY26E FFO is ~36.8x ($235.53 / $6.40 guidance midpoint) and ~32.5x my 2027E FFO of $7.25 - a large premium to REIT peers at 20-25x, justified only if mid-teens FFO growth persists for another two years. The deterministic model's 'Rich vs. its own history' flag (score 30.4) is well earned.

This is a 'priced for continued beats' setup. At ~32.5x 2027E FFO, the market has already capitalized roughly two more years of ~13% FFO growth, so the stock no longer needs a third consecutive guidance raise - it requires one, plus SHO NOI growth staying near 20%. The bull case is mechanical: if 2027 FFO lands at $7.25+ and the multiple holds at 32-33x, you get mid-single-digit to low-double-digit returns with a 1.4% yield; if Q3 2026 (October 26) shows occupancy stalling or RevPOR decelerating, there is no valuation cushion and the multiple - not the earnings - does the damage. Do not anchor on the 122x GAAP P/E either way; the P/E is noise, the FFO multiple is the signal.

As of 2026-09-13, the technical read is 'strong uptrend, short-term rest.' RSI(14) is 47.4 - dead neutral, no overbought or oversold signal. The price is 0.92% below the 20-day SMA and 0.90% below the 50-day SMA, so it has drifted sideways-to-slightly-lower for a few weeks, but it remains 11.32% above the 200-day SMA, which is the mark of an intact primary uptrend. Momentum over the trailing windows: -0.23% (1 week), +2.32% (1 month), +9.98% (3 months), +13.38% (6 months). With the 52-week range at $163.75-$255.20 and the stock at $235.53 (about 78% of that range, 7.7% off the high), there is no urgency to chase - the better entry is either a reclaim of the 20/50-day SMAs on volume or a pullback toward the 200-day in the low-$210s.

• Interest rates and cost of equity: a REIT trading at ~32x forward FFO is acutely duration-sensitive. Rate cuts would lower the discount rate and support the multiple; a renewed rise in the 10-year would pressure it. Welltower's own balance sheet is a cushion (long-term debt of $17.7B, debt/equity 0.425, ~2.7x net debt/adjusted EBITDA, $1.97B cash).
• Demographics: the 80+ population is surging while the caregiver ratio (45-64 year-olds per 80+ senior) is projected to fall below 2.0 by 2041 - the single strongest structural demand tailwind in U.S. real estate, and the core of the bulls' long-term case.
• Healthcare labor and wage inflation: staffing shortages and wage pressure remain the key operating-margin watchpoint for the Seniors Housing Operating portfolio; so far RevPOR growth of 5.2% and pricing power have more than offset it.
• Senior housing supply discipline: post-2022 construction financing constraints have kept new starts low, letting occupancy and rents rise - but any normalization in construction lending would gradually erode that pricing power.
• Cross-border expansion and regulation: the Barchester/UK pipeline adds GBP translation exposure and integration risk, plus the general regulatory/Medicare-Medicaid reimbursement backdrop for healthcare real estate.

• Q3 2026 earnings (expected Monday, October 26, 2026, after the close): the key test of whether SHO spot occupancy holds above 89%, RevPOR keeps compounding, and management delivers a third consecutive upward revision to FFO guidance.
• Closing milestones on the multi-billion-dollar international senior housing pipeline, including Barchester integration in the UK - execution here validates the capital-recycling strategy of selling lower-yielding outpatient medical assets into higher-yielding senior housing.
• Continued dividend growth: the June 2026 15% hike to $0.85/quarter is well covered by a ~53% FFO payout, leaving room for further raises if FFO compounds as guided.
• Rate cuts or a falling 10-year Treasury, which would lower the cost of equity and help sustain the premium multiple the stock carries.
• Quarterly FFO beats versus the $6.36-$6.44 FY26 range - the stock's multiple leaves little room for an in-line or soft quarter.

• Valuation risk is the dominant one: ~36.8x FY26E FFO and ~63x EV/EBITDA leave essentially no margin for error. A growth deceleration from ~40% revenue growth toward mid-single digits would compress the multiple, and the multiple is doing most of the work in the current price.
• Labor cost inflation and healthcare staffing shortages compressing Seniors Housing Operating margins despite pricing power.
• Occupancy or rate-growth deceleration if new senior housing supply returns as construction financing normalizes, or if the RevPOR increases of recent quarters prove to be peak-cycle pricing.
• Execution and currency risk on the large international (Barchester/UK) expansion, plus capital-recycling risk if outpatient medical dispositions do not fetch the assumed prices.
• GAAP earnings quality optics: the -$943.7M operating loss and $96M net income in Q4 2025 shows real impairment exposure in the portfolio, and rising rates would hit both asset marks and Welltower's cost of capital.

Welltower is a genuinely elite franchise - 15.5% same-store NOI growth, 20.5% SHO NOI growth, 25% FFO/share growth, a fortress balance sheet at 2.7x net debt/EBITDA, and a demographic tailwind that is arguably the best in public real estate. But as of 2026-09-13 you are paying ~32.5x 2027E FFO and 13.5x sales for it, well above the stock's own 5-year average P/S of 8.28x, and my math puts fair value around $228 - slightly below the current $235.53. This is a 'hold what you own, don't chase' name: the business is compounding, but the price already assumes the next two years go right, and the risk/reward from here is roughly symmetric at best.

Forward P/FFO on 2027 estimates: I start from the midpoint of management's raised FY26 normalized FFO guidance ($6.40) and apply ~13% growth - a deliberate deceleration from the current +25% FFO/share pace - to get 2027E FFO of ~$7.25/share. I apply a 31.5x multiple, a premium to the ~25x REIT peer norm and to Welltower's own 5-year average, justified by mid-teens SSNOI growth, best-in-class management and 2.7x net debt/EBITDA, but below the ~32.5x forward multiple the stock currently commands because that level requires flawless multi-year execution. $7.25 x 31.5 = ~$228, roughly 3% below the 2026-09-13 price of $235.53.